公开(公告)号：US08940499B2

公开(公告)日：2015-01-27

申请号：US12580474

申请日：2009-10-16

Applicant: Yuji Kuang ,  Baohua Zhang ,  Bing Xu ,  Jianhui Shao ,  Ting Lei ,  Li Zhang

Inventor： Yuji Kuang ,  Baohua Zhang ,  Bing Xu ,  Jianhui Shao ,  Ting Lei ,  Li Zhang

IPC: C07D215/36 ,  C07D215/12 ,  C07D215/14 ,  C07D215/18 ,  C07D215/04 ,  C07D215/10 ,  G01N33/80 ,  C09K11/06 ,  G01N33/50 ,  G01N33/58

CPC classification number: G01N33/80 ,  C09K11/06 ,  C09K2211/1011 ,  C09K2211/1029 ,  C09K2211/1037 ,  G01N15/1459 ,  G01N33/5094 ,  G01N33/582 ,  G01N2015/1006 ,  G01N2015/1402

Abstract: The present disclosure provides a reagent for blood analysis which may include: (1) a compound having the general formula I as a fluorescent dye, wherein n, X, R1, R2, R3, R4, R5 and Y− are as defined in the specification; (2) a surfactant selected from cationic surfactants, zwitterionic surfactants and anionic surfactants. The present disclosure also provides a method to perform blood analysis including the following steps of: (a) mixing the blood sample with the reagent for blood analysis disclosed to form a cell suspension; (b) detecting the scattered light signals and fluorescence signals from the cells; and (c) differentiating and counting the cells in the blood in terms of the scattered light signals and fluorescence signals.

Abstract translation: 本公开提供了用于血液分析的试剂，其可以包括：（1）具有通式I的化合物作为荧光染料，其中n，X，R 1，R 2，R 3，R 4，R 5和Y - 如 规范; （2）选自阳离子表面活性剂，两性离子表面活性剂和阴离子表面活性剂的表面活性剂。 本公开还提供了进行血液分析的方法，包括以下步骤：（a）将血液样品与所公开的用于血液分析的试剂混合以形成细胞悬浮液; （b）检测来自细胞的散射光信号和荧光信号; 和（c）根据散射光信号和荧光信号来区分和计数血液中的细胞。

公开(公告)号：US08697648B2

公开(公告)日：2014-04-15

申请号：US13503194

申请日：2010-10-20

Applicant: Zhi-Ren Liu ,  Jie Yang ,  Bing Xu ,  Wangda Zhou ,  Shenghui Xue

Inventor： Zhi-Ren Liu ,  Jie Yang ,  Bing Xu ,  Wangda Zhou ,  Shenghui Xue

IPC: A61K38/26 ,  A61K38/00 ,  C07K14/605 ,  C07K19/00 ,  A61K47/48 ,  A61K49/08

CPC classification number: A61K38/26 ,  A61K38/00 ,  A61K47/60 ,  A61K49/085 ,  C07K14/605 ,  C07K2319/00

Abstract: The 30 amino acid peptide GLP-1 has been integrated into the stable host protein human calbindin D9k. The fusion protein binds to GLP-1R. The fusion protein agents can be useful for both diabetes treatment and GLP-1R receptor targeting MR imaging. The fusion protein comprises a first peptide that selectively binds to a site of a target cell and linked to a second peptide, where the fusion protein is more stable than the first peptide alone and may further comprise a detectable label. The first peptide of the fusion protein may be glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1 (GLP-1)(7-36), or glucagon-like peptide-1 (GLP-1) (9-36), or a conservative variant thereof.

Abstract translation: 已将30个氨基酸的肽GLP-1整合到稳定的宿主蛋白人卡金登丁D9k中。 融合蛋白与GLP-1R结合。 融合蛋白剂可用于糖尿病治疗和靶向MR成像的GLP-1R受体。 融合蛋白包含选择性结合靶细胞位点并与第二肽连接的第一肽，其中融合蛋白比单独的第一肽更稳定，并且还可以包含可检测标记。 融合蛋白的第一个肽可以是胰高血糖素样肽-1（GLP-1），胰高血糖素样肽-1（GLP-1）（7-36）或胰高血糖素样肽-1（GLP-1） （9-36）或其保守变体。

公开(公告)号：US08284860B2

公开(公告)日：2012-10-09

申请号：US12262575

申请日：2008-10-31

Applicant: Bing Xu ,  Daniel B. Schwartz ,  Clive K. Tang

Inventor： Bing Xu ,  Daniel B. Schwartz ,  Clive K. Tang

IPC: H04L25/49 ,  H04B1/04

CPC classification number: H04B1/0475 ,  H03F1/3241 ,  H04B2001/0425

Abstract: Apparatus, systems, and methods are provided for controlling the output of a transmitter using a digital error signal. A method comprises generating a digital reference signal based on a baseband input signal and converting the digital reference signal to an analog reference signal. The method further comprises generating an analog error signal in response to a difference between the analog reference signal and an analog output signal. The method further comprises generating a digital error signal from the analog error signal, and generating an input signal for the transmitter based on the baseband input signal and the digital error signal.

Abstract translation: 提供装置，系统和方法，用于使用数字误差信号来控制发射机的输出。 一种方法包括基于基带输入信号产生数字参考信号并将数字参考信号转换为模拟参考信号。 该方法还包括响应于模拟参考信号和模拟输出信号之间的差异产生模拟误差信号。 该方法还包括从模拟误差信号产生数字误差信号，并且基于基带输入信号和数字误差信号产生用于发射机的输入信号。

公开(公告)号：US20120244080A1

公开(公告)日：2012-09-27

申请号：US13503194

申请日：2010-10-20

Applicant: Zhi-Ren Liu ,  Jie Yang ,  Bing Xu ,  Wangda Zhou ,  Shenghui Xue

Inventor： Zhi-Ren Liu ,  Jie Yang ,  Bing Xu ,  Wangda Zhou ,  Shenghui Xue

IPC: C07K19/00 ,  G01N21/75 ,  A61K49/14 ,  C12N5/071

CPC classification number: A61K38/26 ,  A61K38/00 ,  A61K47/60 ,  A61K49/085 ,  C07K14/605 ,  C07K2319/00

Abstract: Glucagon-like peptide-1 (GLP-1) is a member of a large family of incretin hormones secreted in nutrient-dependent response. GLP-1 acts on GLP-1 receptor (GLP-1 R) that is highly expressed on pancreatic β-cells. The peptide has great potential for development of diabetes treatment and diagnosis. However, the pharmaceutical effects of the peptide suffer from in vivo instability and short life due to degradation by Dipeptidylpeptidase-1 (DPP-4). The 30 amino acid peptide GLP-1 has been integrated into a stable host protein human calbindin D9k. The fusion protein binds to GLP-1 R as demonstrated by immunostaining analyses of GLP-1 R expressing cells. The fusion protein agents can be useful for both diabetes treatment and GLP-1 R receptor targeting MR imaging. The fusion protein has a size about 14 kDa, which enables efficient tissue penetration and retention, and an extended circulation time, is stable, remaining intact and retaining activity after 48 hours incubation with 75% human serum. The protein retains its native folded structure after boiling for ten minutes forming the basis of an experimental protocol for large scale production of the fusion protein (>30 mg/l bacterial culture). No toxicity has been observed with tests on mice. One aspect of the disclosure, therefore, provides a fusion protein comprising a first peptide characterized by selectively binding to a site of a target cell and linked to a second peptide, where the fusion protein is more stable than the first peptide alone. In embodiments of this aspect of the disclosure, the fusion protein may further comprise a detectable label attached thereto. In some embodiments of this aspect of the disclosure, the first peptide of the fusion protein may be glucagon-like peptide-1 (GLP-1), glucagon-like peptide-1 (GLP-1)(7-36), or glucagon-like peptide-1 (GLP-1) (9-36), or a conservative variant thereof.

Abstract translation: 胰高血糖素样肽-1（GLP-1）是营养依赖性反应中分泌的大肠激素的成员之一。 GLP-1作用于在胰腺细胞上高度表达的GLP-1受体（GLP-1R）。 该肽具有发展糖尿病治疗和诊断的巨大潜力。 然而，由于二肽基肽酶-1（DPP-4）的降解，肽的药物作用遭受体内不稳定性和短寿命。 30个氨基酸的肽GLP-1已经被整合到稳定的宿主蛋白人类calbindin D9k中。 如通过GLP-1R表达细胞的免疫染色分析所证明的，融合蛋白与GLP-1R结合。 融合蛋白剂可用于糖尿病治疗和靶向MR-1的受体受体。 融合蛋白具有约14kDa的大小，其能够有效的组织穿透和保留，并且延长的循环时间是稳定的，在75％人血清孵育48小时后保持完整和保留活性。 蛋白质在煮沸10分钟后保持其天然折叠结构，形成用于大规模生产融合蛋白（> 30mg / l细菌培养物）的实验方案的基础。 在小鼠试验中没有观察到毒性。 因此，本公开的一个方面提供了包含第一肽的融合蛋白，其特征在于选择性结合靶细胞的位点并连接到第二个肽，其中融合蛋白比单独的第一个肽更稳定。 在本公开的该方面的实施方案中，融合蛋白还可包含附着于其上的可检测标记。 在本公开的该方面的一些实施方案中，融合蛋白的第一肽可以是胰高血糖素样肽-1（GLP-1），胰高血糖素样肽-1（GLP-1）（7-36）或胰高血糖素 样肽-1（GLP-1）（9-36）或其保守变体。

公开(公告)号：US08204456B2

公开(公告)日：2012-06-19

申请号：US12882498

申请日：2010-09-15

Applicant: Bing Xu ,  Clive Tang ,  Mahibur Rahman

Inventor： Bing Xu ,  Clive Tang ,  Mahibur Rahman

IPC: H04B1/04

CPC classification number: H04B1/0475 ,  H03F1/3241 ,  H03F3/24 ,  H04B2001/0425

Abstract: In accordance with some embodiments of the present disclosure, a method may include digitally pre-distorting a digital baseband signal with an opposite phase of a C-IM3 distortion term such that the pre-distortion and C-IM3 distortion cancel each other out in a transmitter. The method may also include digitally conditioning the pre-distorted digital signal in order to provide a flat amplitude response of a composite filter comprising a baseband filter and a digital half-band filter of the transmitter, and to provide a linear phase response for the composite filter.

Abstract translation: 根据本公开的一些实施例，一种方法可以包括以C-IM3失真项的相反相数字预失真数字基带信号，使得预失真和C-IM3失真在一个 发射机。 该方法还可以包括对预失真的数字信号进行数字调节，以便提供包括发射机的基带滤波器和数字半带滤波器的复合滤波器的平坦振幅响应，并且为复合信号提供线性相位响应 过滤。

公开(公告)号：US20120064847A1

公开(公告)日：2012-03-15

申请号：US12882498

申请日：2010-09-15

Applicant: Bing Xu ,  Clive Tang ,  Mahibur Rahman

Inventor： Bing Xu ,  Clive Tang ,  Mahibur Rahman

IPC: H04B1/04

CPC classification number: H04B1/0475 ,  H03F1/3241 ,  H03F3/24 ,  H04B2001/0425

Abstract: In accordance with some embodiments of the present disclosure, a method may include digitally pre-distorting a digital baseband signal with an opposite phase of a C-IM3 distortion term such that the pre-distortion and C-IM3 distortion cancel each other out in a transmitter. The method may also include digitally conditioning the pre-distorted digital signal in order to provide a flat amplitude response of a composite filter comprising a baseband filter and a digital half-band filter of the transmitter, and to provide a linear phase response for the composite filter.

Abstract translation: 根据本公开的一些实施例，一种方法可以包括以C-IM3失真项的相反相数字预失真数字基带信号，使得预失真和C-IM3失真在一个 发射机。 该方法还可以包括对预失真的数字信号进行数字调节，以便提供包括发射机的基带滤波器和数字半带滤波器的复合滤波器的平坦振幅响应，并且为复合信号提供线性相位响应 过滤。

公开(公告)号：US08000665B2

公开(公告)日：2011-08-16

申请号：US12259867

申请日：2008-10-28

Applicant: Kenneth Stebbings ,  Vivek Bhan ,  Daniel B. Schwartz ,  Bing Xu

Inventor： Kenneth Stebbings ,  Vivek Bhan ,  Daniel B. Schwartz ,  Bing Xu

IPC: H03G3/00 ,  H04B1/04 ,  H04L25/03

CPC classification number: H04B1/0475 ,  H03F1/02 ,  H03F1/0266 ,  H03F1/3247 ,  H03F3/195 ,  H03F3/24 ,  H03G3/3042 ,  H04B2001/045 ,  H04L27/368

Abstract: Systems and methods are provided for controlling headroom of an amplifier (e.g., in a transmitter). A method comprises obtaining a target output power for a current interval and obtaining a target headroom for a subsequent interval. The method continues by adjusting, during the current interval, the power output capability of the amplifier based on the target headroom and adjusting the input power of an input signal based on the target output power, such that the output power of the amplifier is substantially constant during the current interval as the power output capability of the amplifier is adjusted.

Abstract translation: 提供了用于控制放大器（例如，在发射机中）的余量的系统和方法。 一种方法包括获得当前间隔的目标输出功率并获得用于后续间隔的目标余量。 该方法通过在当前时间间隔期间基于目标余量调整放大器的功率输出能力并基于目标输出功率调整输入信号的输入功率，使得放大器的输出功率基本上恒定 在当前时间间隔内，调节放大器的功率输出能力。

公开(公告)号：US07983235B2

公开(公告)日：2011-07-19

申请号：US11935156

申请日：2007-11-05

Applicant: Clinton C Powell ,  Kuor-Hsin Chang ,  Bing Xu

Inventor： Clinton C Powell ,  Kuor-Hsin Chang ,  Bing Xu

IPC: H04W4/00 ,  H04J3/06 ,  H04B1/02 ,  H04L27/20

CPC classification number: H04W4/008 ,  H04B1/707 ,  H04L27/20 ,  H04L27/38 ,  H04W4/80 ,  H04W28/06 ,  H04W28/22 ,  H04W56/001 ,  H04W84/10

Abstract: In a wireless 802.15.4 communication system (300), a high-speed data frame structure (340) is provided which uses the 802.15.4 SHR structure that is spread modulated to obtain the synchronization benefits of the 802.15.4 protocol, but which uses a modified data frame structure for the payload portion without using spreading to thereby improve its transmission efficiency. The transmission efficiency can be further increased by increasing the size of the data payload (and correspondingly, the frame length size).

Abstract translation: 在无线802.15.4通信系统（300）中，提供了高速数据帧结构（340），其使用被扩频调制的802.15.4 SHR结构来获得802.15.4协议的同步优点，但是哪个 对于有效载荷部分使用经修改的数据帧结构，而不使用扩展，从而提高其传输效率。 通过增加数据有效载荷的大小（相应地，帧长度大小），可以进一步提高传输效率。

公开(公告)号：US20110028676A1

公开(公告)日：2011-02-03

申请号：US12701986

申请日：2010-02-08

Applicant: Patrick A. Anquetil ,  Ian W. Hunter ,  John D. Madden ,  Peter G. Madden ,  Anthony E. Pullen ,  Timothy M. Swager ,  Bing Xu ,  Hsiao-hua Yu

Inventor： Patrick A. Anquetil ,  Ian W. Hunter ,  John D. Madden ,  Peter G. Madden ,  Anthony E. Pullen ,  Timothy M. Swager ,  Bing Xu ,  Hsiao-hua Yu

IPC: C08G65/38

CPC classification number: H01B1/127 ,  C08G61/122 ,  H01B1/128

Abstract: The synthesis of thiophene based conducting polymer molecular actuators, exhibiting electrically triggered molecular conformational transitions is reported. Actuation is believed to be the result of conformational rearrangement of the polymer backbone at the molecular level, not simply ion intercalation in the bulk polymer chain upon electrochemical activation. Molecular actuation results from π-π stacking of thiophene oligomers upon oxidation, producing a reversible molecular displacement that leads to surprising material properties, such as electrically controllable porosity and large strains. The existence of active molecular conformational changes is supported by in situ electrochemical data. Single molecule techniques have been used to characterize the molecular actuators.

Abstract translation: 报道了噻吩基导电聚合物分子致动器的合成，显示出电触发的分子构象转变。 认为激发是聚合物骨架在分子水平上的构象重排的结果，而不是简单地在电化学活化时主体聚合物链中的离子嵌入。 分子致动结果来自＆pgr; - ＆pgr; 在氧化时堆叠噻吩低聚物，产生可逆的分子位移，导致令人惊奇的材料性质，例如电可控孔隙率和大应变。 活性分子构象变化的存在由原位电化学数据支持。 已经使用单分子技术来表征分子致动器。

公开(公告)号：US20100111238A1

公开(公告)日：2010-05-06

申请号：US12262575

申请日：2008-10-31

Applicant: Bing Xu ,  Daniel B. Schwartz ,  Clive K. Tang

Inventor： Bing Xu ,  Daniel B. Schwartz ,  Clive K. Tang

IPC: H03D1/04

CPC classification number: H04B1/0475 ,  H03F1/3241 ,  H04B2001/0425

Abstract: Apparatus, systems, and methods are provided for controlling the output of a transmitter using a digital error signal. A method comprises generating a digital reference signal based on a baseband input signal and converting the digital reference signal to an analog reference signal. The method further comprises generating an analog error signal in response to a difference between the analog reference signal and an analog output signal. The method further comprises generating a digital error signal from the analog error signal, and generating an input signal for the transmitter based on the baseband input signal and the digital error signal.

Abstract translation: 提供装置，系统和方法，用于使用数字误差信号来控制发射机的输出。 一种方法包括基于基带输入信号产生数字参考信号并将数字参考信号转换为模拟参考信号。 该方法还包括响应于模拟参考信号和模拟输出信号之间的差异产生模拟误差信号。 该方法还包括从模拟误差信号产生数字误差信号，并且基于基带输入信号和数字误差信号产生用于发射机的输入信号。